252 related articles for article (PubMed ID: 19228727)
1. Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias.
Mitsiades CS; Rouleau C; Echart C; Menon K; Teicher B; Distaso M; Palumbo A; Boccadoro M; Anderson KC; Iacobelli M; Richardson PG
Clin Cancer Res; 2009 Feb; 15(4):1210-21. PubMed ID: 19228727
[TBL] [Abstract][Full Text] [Related]
2. Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial.
Palumbo A; Larocca A; Genuardi M; Kotwica K; Gay F; Rossi D; Benevolo G; Magarotto V; Cavallo F; Bringhen S; Rus C; Masini L; Iacobelli M; Gaidano G; Mitsiades C; Anderson K; Boccadoro M; Richardson P;
Haematologica; 2010 Jul; 95(7):1144-9. PubMed ID: 20053869
[TBL] [Abstract][Full Text] [Related]
3. Update on the use of defibrotide.
Guglielmelli T; Bringhen S; Palumbo A
Expert Opin Biol Ther; 2012 Mar; 12(3):353-61. PubMed ID: 22283742
[TBL] [Abstract][Full Text] [Related]
4. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
Li J; Favata M; Kelley JA; Caulder E; Thomas B; Wen X; Sparks RB; Arvanitis A; Rogers JD; Combs AP; Vaddi K; Solomon KA; Scherle PA; Newton R; Fridman JS
Neoplasia; 2010 Jan; 12(1):28-38. PubMed ID: 20072651
[TBL] [Abstract][Full Text] [Related]
5. Defibrotide blunts the prothrombotic effect of thalidomide on endothelial cells.
Echart CL; Somaini S; Distaso M; Palumbo A; Richardson PG; Fareed J; Iacobelli M
Clin Appl Thromb Hemost; 2012; 18(1):79-86. PubMed ID: 21733935
[TBL] [Abstract][Full Text] [Related]
6. The importance of endothelial protection: the emerging role of defibrotide in reversing endothelial injury and its sequelae.
Richardson PG; Palomo M; Kernan NA; Hildebrandt GC; Chao N; Carreras E
Bone Marrow Transplant; 2021 Dec; 56(12):2889-2896. PubMed ID: 34584241
[TBL] [Abstract][Full Text] [Related]
7. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
8. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.
Azab AK; Runnels JM; Pitsillides C; Moreau AS; Azab F; Leleu X; Jia X; Wright R; Ospina B; Carlson AL; Alt C; Burwick N; Roccaro AM; Ngo HT; Farag M; Melhem MR; Sacco A; Munshi NC; Hideshima T; Rollins BJ; Anderson KC; Kung AL; Lin CP; Ghobrial IM
Blood; 2009 Apr; 113(18):4341-51. PubMed ID: 19139079
[TBL] [Abstract][Full Text] [Related]
9. Homoharringtonine enhances bortezomib antimyeloma activity in myeloma cells adhesion to bone marrow stromal cells and in SCID mouse xenografts.
Chen P; Yuan Q; Yang H; Wen X; You P; Hou D; Xie J; Cheng Y; Huang H
Leuk Res; 2017 Jun; 57():119-126. PubMed ID: 28463768
[TBL] [Abstract][Full Text] [Related]
10. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
[TBL] [Abstract][Full Text] [Related]
11. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
Tai YT; Fulciniti M; Hideshima T; Song W; Leiba M; Li XF; Rumizen M; Burger P; Morrison A; Podar K; Chauhan D; Tassone P; Richardson P; Munshi NC; Ghobrial IM; Anderson KC
Blood; 2007 Sep; 110(5):1656-63. PubMed ID: 17510321
[TBL] [Abstract][Full Text] [Related]
12. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo.
Mitsiades CS; Ocio EM; Pandiella A; Maiso P; Gajate C; Garayoa M; Vilanova D; Montero JC; Mitsiades N; McMullan CJ; Munshi NC; Hideshima T; Chauhan D; Aviles P; Otero G; Faircloth G; Mateos MV; Richardson PG; Mollinedo F; San-Miguel JF; Anderson KC
Cancer Res; 2008 Jul; 68(13):5216-25. PubMed ID: 18593922
[TBL] [Abstract][Full Text] [Related]
13. Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo.
Hamasaki M; Hideshima T; Tassone P; Neri P; Ishitsuka K; Yasui H; Shiraishi N; Raje N; Kumar S; Picker DH; Jacob GS; Richardson PG; Munshi NC; Anderson KC
Blood; 2005 Jun; 105(11):4470-6. PubMed ID: 15705788
[TBL] [Abstract][Full Text] [Related]
14. Myeloma-Modified Adipocytes Exhibit Metabolic Dysfunction and a Senescence-Associated Secretory Phenotype.
Fairfield H; Dudakovic A; Khatib CM; Farrell M; Costa S; Falank C; Hinge M; Murphy CS; DeMambro V; Pettitt JA; Lary CW; Driscoll HE; McDonald MM; Kassem M; Rosen C; Andersen TL; van Wijnen AJ; Jafari A; Reagan MR
Cancer Res; 2021 Feb; 81(3):634-647. PubMed ID: 33218968
[TBL] [Abstract][Full Text] [Related]
15. Toll-like receptor (TLR)-1/2 triggering of multiple myeloma cells modulates their adhesion to bone marrow stromal cells and enhances bortezomib-induced apoptosis.
Abdi J; Mutis T; Garssen J; Redegeld FA
PLoS One; 2014; 9(5):e96608. PubMed ID: 24794258
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a novel mouse model of multiple myeloma and its use in preclinical therapeutic assessment.
Fryer RA; Graham TJ; Smith EM; Walker-Samuel S; Morgan GJ; Robinson SP; Davies FE
PLoS One; 2013; 8(2):e57641. PubMed ID: 23437401
[TBL] [Abstract][Full Text] [Related]
17. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.
Ikeda H; Hideshima T; Fulciniti M; Lutz RJ; Yasui H; Okawa Y; Kiziltepe T; Vallet S; Pozzi S; Santo L; Perrone G; Tai YT; Cirstea D; Raje NS; Uherek C; Dälken B; Aigner S; Osterroth F; Munshi N; Richardson P; Anderson KC
Clin Cancer Res; 2009 Jun; 15(12):4028-37. PubMed ID: 19509164
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma.
Jakubikova J; Cervi D; Ooi M; Kim K; Nahar S; Klippel S; Cholujova D; Leiba M; Daley JF; Delmore J; Negri J; Blotta S; McMillin DW; Hideshima T; Richardson PG; Sedlak J; Anderson KC; Mitsiades CS
Haematologica; 2011 Aug; 96(8):1170-9. PubMed ID: 21712538
[TBL] [Abstract][Full Text] [Related]
19. The use of defibrotide in blood and marrow transplantation.
Richardson PG; Carreras E; Iacobelli M; Nejadnik B
Blood Adv; 2018 Jun; 2(12):1495-1509. PubMed ID: 29945939
[TBL] [Abstract][Full Text] [Related]
20. PI3K/Akt inhibitor LY294002 potentiates homoharringtonine antimyeloma activity in myeloma cells adhered to stromal cells and in SCID mouse xenograft.
Chen P; Wen X; Wang B; Hou D; Zou H; Yuan Q; Yang H; Xie J; Huang H
Ann Hematol; 2018 May; 97(5):865-875. PubMed ID: 29450644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]